Biggest changeAs a result, the Lender’s financing obligations have terminated pursuant to the terms of the Facility Agreement. 54 Until we close one or more equity financing transactions in an aggregate amount of at least $5 million (including the conversion of the Credit Facility), we had the right to convert into ordinary share up to $1.5 million, including accrued interest, of a loan extended or to be extended to us by the Lender, or the January 2024 Conversion Loan Amount, in connection with and in the framework of a financing transaction of ours on the date that follows the date upon which we notified the Lender of such financing transaction, which conversion will occur upon the same terms.
Biggest changeUntil we close one or more equity financing transactions in an aggregate amount of at least $5 million (including the conversion of the Credit Facility), we had the right to convert into ordinary share up to $1.5 million, including accrued interest, of a loan extended or to be extended to us by the Lender, or the January 2024 Conversion Loan Amount, in connection with and in the framework of a financing transaction of ours on the date that follows the date upon which we notified the Lender of such financing transaction, which conversion will occur upon the same terms. 56 As part of the Facility Agreement, we issued a warrant, or the January 2024 Facility Warrant, to the Lender to purchase 80,645 of our ordinary shares representing an aggregate exercise amount of $7.5 million, with a per share exercise price of $93.00, subject to certain adjustments and certain anti-dilution protection, representing a 150% premium of the closing share price of our ordinary shares on January 5, 2024.
As the warrants meet the definition of a derivative as contemplated in ASC 815, the warrants are recorded as derivative liabilities on the balance sheet and measured at fair value at inception and at each reporting date thereafter in accordance with ASC 820 “Fair Value Measurement”, with changes in fair value recognized in the condensed statements of comprehensive loss in the period of change Under ASC 815-40, contracts that are not indexed to the Company’s own equity are classified as liabilities recorded at fair value, As such, the Company classifies the SEPA Agreement entered into as a derivative instrument measured at fair value at each reporting period, as settlement provisions under this agreement are not indexed to the Company’s own equity.
As the warrants meet the definition of a derivative as contemplated in ASC 815, the warrants are recorded as derivative liabilities on the balance sheet and measured at fair value at inception and at each reporting date thereafter in accordance with ASC 820 “Fair Value Measurement”, with changes in fair value recognized in the condensed statements of comprehensive loss in the period of change Under ASC 815-40, contracts that are not indexed to the Company’s own equity are classified as liabilities recorded at fair value, As such, the Company classifies the SEPA Agreement entered into as a derivative instrument measured at fair value at each reporting period, as settlement provisions under this agreement are not indexed to the Company’s own equity. 59
Operating and Financial Review and Prospectus—Operating Results” and elsewhere in this Annual Report, we are not aware of any trends, uncertainties, demands, commitments or events for the period from January 1, 2024 to December 31, 2024 that are reasonably likely to have a material effect on our total revenues, income, profitability, liquidity or capital resources, or that caused the disclosed financial information to be not necessarily indicative of future operating results or financial condition.
Operating and Financial Review and Prospectus-Operating Results” and elsewhere in this Annual Report, we are not aware of any trends, uncertainties, demands, commitments or events for the period from January 1, 2025 to December 31, 2025 that are reasonably likely to have a material effect on our total revenues, income, profitability, liquidity or capital resources, or that caused the disclosed financial information to be not necessarily indicative of future operating results or financial condition. 58 E.
E. Critical Accounting Estimates We describe our significant accounting policies more fully in Note 2 to our financial statements for the year ended December 31, 2024. We believe that the accounting policies below are critical in order to fully understand and evaluate our financial condition and results of operations. We prepare our financial statements in accordance with U.S. GAAP.
Critical Accounting Estimates We describe our significant accounting policies more fully in Note 2 to our financial statements for the year ended December 31, 2025. We believe that the accounting policies below are critical in order to fully understand and evaluate our financial condition and results of operations. We prepare our financial statements in accordance with U.S. GAAP.
Operating Results— Comparison of the year ended December 31, 2024 to the year ended December 31, 2023— Research and Development Expenses.” D. Trend Information Other than as disclosed in “Item 5.
Operating Results- Comparison of the year ended December 31, 2025 to the year ended December 31, 2024- Research and Development Expenses.” D. Trend Information Other than as disclosed in “Item 5.
We expect that our cash and cash equivalents as of the issuance date of this annual report and the future expected cash flow from sales will be sufficient for at least 27 months of operations. Without derogating from the foregoing estimate regarding our existing capital resources and cash flows from operations, we may decide to raise additional funds in 2025.
We expect that our cash and cash equivalents as of the issuance date of this annual report and the future expected cash flow from sales will be sufficient for at least 18 months of operations. Without derogating from the foregoing estimate regarding our existing capital resources and cash flows from operations, we may decide to raise additional funds in 2026.
The January 2024 PIPE Ordinary Share Warrants are exercisable upon issuance at an exercise price of $0.98475 per ordinary share, subject to certain adjustments and certain anti-dilution protection set forth therein, and have a 5.5-year term from the issuance date.
The January 2024 PIPE Ordinary Share Warrants are exercisable upon issuance at an exercise price of $29.5425 per ordinary share, subject to certain adjustments and certain anti-dilution protection set forth therein, and have a 5.5-year term from the issuance date.
The following discussion of the financial condition and results of operations is for the years ended December 31, 2024 and 2023.
The following discussion of the financial condition and results of operations is for the years ended December 31, 2025 and 2024.
As consideration for Yorkville’s irrevocable commitment to purchase our ordinary shares up to the Commitment Amount, we issued 288,684 ordinary shares, or the Commitment Shares, to Yorkville and also paid a $10,000 structuring fee to an affiliate of Yorkville.
As consideration for Yorkville’s irrevocable commitment to purchase our ordinary shares up to the Commitment Amount, we issued 9,623 ordinary shares, or the Commitment Shares, to Yorkville and also paid a $10,000 structuring fee to an affiliate of Yorkville.
The remaining amount of approximately $3,032,000 was used for professional services, marketing, travel, rent and other miscellaneous expenses. Investing Activities Net cash used in investing activities of $30,000 during 2024 and $152,000 during 2023, primarily reflected the purchase of fixed assets in both periods.
The remaining amount of approximately $3,733,000 was used for professional services, marketing, travel, rent and other miscellaneous expenses. Investing Activities Net cash used in investing activities of $125,000 during 2025 and $30,000 during 2024, primarily reflected the purchase of fixed assets in both periods.
Liquidity and Capital Resources Overview Since our inception through December 31, 2024, we have funded our operations principally with approximately $86 million (net of issuance expenses) from the issuance of ordinary shares, preferred shares, and warrants in public and private offerings. As of December 31, 2024, we had approximately $17.5 in cash and cash equivalents.
B. Liquidity and Capital Resources Overview Since our inception through December 31, 2025, we have funded our operations principally with approximately $97 million (net of issuance expenses) from the issuance of ordinary shares, preferred shares, and warrants in public and private offerings. As of December 31, 2025, we had approximately $20 million in cash and cash equivalents.
Following the closing of the January 2024 PIPE, the exercise price of the January 2024 Facility Warrant was adjusted to $0.408 which is the effective price per ordinary share in the January 2024 PIPE, or the January 2024 Facility Warrant Adjusted Exercise Price, and the number of ordinary shares issuable upon the exercise of the January 2024 Facility Warrant was also adjusted to a total 18,382,353, or the January 2024 Facility Warrant Adjusted Shares, such that the product of the January 2024 Facility Warrant Adjusted Exercise Price and the January 2024 Facility Warrant Adjusted Shares is equal to an aggregate exercise amount of $7.5 million.
Following the closing of the January 2024 PIPE, the exercise price of the January 2024 Facility Warrant was adjusted to $12.24 which is the effective price per ordinary share in the January 2024 PIPE, or the January 2024 Facility Warrant Adjusted Exercise Price, and the number of ordinary shares issuable upon the exercise of the January 2024 Facility Warrant was also adjusted to a total 612,745, or the January 2024 Facility Warrant Adjusted Shares, such that the product of the January 2024 Facility Warrant Adjusted Exercise Price and the January 2024 Facility Warrant Adjusted Shares is equal to an aggregate exercise amount of $7.5 million.
Our management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgment and assumptions can affect reported amounts and disclosures made.
Our management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgment and assumptions can affect reported amounts and disclosures made. Actual results could differ from those estimates.
Actual results could differ from those estimates. 57 Derivatives and warrants liabilities The Company evaluated the warrants in accordance with ASC 815 “Derivatives and Hedging - Contracts in Entity’s Own Equity” (“ASC 815”) to determine whether warrants should be classified as liabilities or shareholders’ equity.
Derivatives and warrants liabilities The Company evaluated the warrants in accordance with ASC 815 “Derivatives and Hedging - Contracts in Entity’s Own Equity” (“ASC 815”) to determine whether warrants should be classified as liabilities or shareholders’ equity.
Contractual Obligations The following table summarizes our contractual obligations at December 31, 2024: Total Less than 1 year 1-3 years 3-5 years More than 5 years (in thousands of U.S. dollars) Operating leases $ 541 $ 320 $ 221 $ - $ — 56 C. Research and development, patents and licenses, etc.
Contractual Obligations The following table summarizes our contractual obligations as of December 31, 2025: Total Less than 1 year 1-3 years 3-5 years More than 5 years (in thousands of U.S. dollars) Operating leases $ 253 $ 253 $ - $ - $ - C. Research and development, patents and licenses, etc.
Our future capital requirements will depend on many factors, including: ● the progress and costs of our research and development activities; ● the costs of manufacturing our products; ● the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights; ● the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; and ● the magnitude of our general and administrative expenses.
Our future capital requirements will depend on many factors, including: ● the progress and costs of our research and development activities; ● the costs of manufacturing our products; ● the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights; ● the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; and ● the magnitude of our general and administrative expenses. 57 To date, we have not generated significant revenues from its activities and have incurred substantial operating losses.
We expect that we will require substantial additional capital to complete the development of additional features of our system according to customers’ requirements, including algorithm optimization, cognitive layer development, system minimization and optical development, as well as to commercialize our products.
As of December 31, 2025, our cash and cash equivalents were $19.96 million. We expect that we will require substantial additional capital to complete the development of additional features of our system according to customers’ requirements, including algorithm optimization, cognitive layer development, system minimization and optical development, as well as to commercialize our products.
Following such conversion, we issued to the Lender (as defined below) (i) a pre-funded warrant to purchase up to 507,743 ordinary shares, or the Facility Conversion Pre-Funded Warrant and (ii) a warrant to purchase up to 761,615 ordinary shares, or the Facility Conversion Ordinary Share Warrant.
Following such conversion, we issued to the Lender (as defined below) (i) a pre-funded warrant to purchase up to 16,925 ordinary shares, or the Facility Conversion Pre-Funded Warrant and (ii) a warrant to purchase up to 25,387 ordinary shares, or the Facility Conversion Ordinary Share Warrant.
To date, we have not generated significant revenues from its activities and have incurred substantial operating losses. We expect that we will continue to generate substantial operating losses and will continue to fund our operations primarily through the utilization of our current financial resources, sales of our products, and through additional raises of capital.
We expect that we will continue to generate substantial operating losses and will continue to fund our operations primarily through the utilization of our current financial resources, sales of our products, and through additional raises of capital.
Financing Activities Net cash provided by financing activities in the year ended December 31, 2024, consisted of $23,918,000 primarily in proceeds from the issuance of ordinary shares and warrants, net of issuance expenses (including in relation to the SEPA (as defined below) and the January 2024 PIPE) and proceeds from exercise of warrants that were issued in connection with the January 2024 PIPE and January 2024 Facility Warrants.
See “Standby Equity Purchase Agreement (October 2024), “At-the-Market Sales Agreement (April 2025)” and “Execution of Credit Facility Agreement and Issuance of Warrant (January 2024)”. 54 Net cash provided by financing activities in the year ended December 31, 2024, consisted of $23,918,000 primarily in proceeds from the issuance of ordinary shares and warrants, net of issuance expenses (including in relation to the SEPA (as defined below) and the January 2024 PIPE) and proceeds from exercise of warrants that were issued in connection with the January 2024 PIPE and January 2024 Facility Warrants.
The table below presents our cash flows for the periods indicated: December 31, December 31, (in thousands of USD) 2024 2023 Operating activities $ (9,682 ) $ (10,518 ) Investing activities $ (30 ) $ (152 ) Financing activities $ 23,918 $ 5,397 Effect of exchange rate changes on cash and cash equivalents (27 ) 70 Net increase (decrease) in cash and cash equivalents $ 14,179 $ (5,203 ) Operating Activities Net cash used in operating activities of $9,682,000 during the year ended December 31, 2024, was primarily used for payment of an aggregate of approximately $5,949,000 in salaries and related personnel expenses.
The table below presents our cash flows for the periods indicated: December 31, December 31, (in thousands of USD) 2025 2024 Operating activities $ (9,122 ) $ (9,682 ) Investing activities $ (125 ) $ (30 ) Financing activities $ 11,789 $ 23,918 Effect of exchange rate changes on cash and cash equivalents $ 219 $ (27 ) Net increase in cash and cash equivalents $ 2,761 $ 14,179 Operating Activities Net cash used in operating activities of $9,122,000 during the year ended December 31, 2025, was primarily used for payment of an aggregate of approximately $7,410,000 in salaries and related personnel expenses.
Private Placement (January 2024) On January 18, 2024, we entered into a binding term sheet directly with a global investment firm, or the Lead Investor, for the purchase and sale in a private placement, or the January 2024 PIPE, of units, or the Units, consisting of (i) one of our ordinary shares and/or pre-funded warrants to purchase our ordinary shares and (ii) one and a half warrants to purchase our ordinary shares to the Lead Investor and other investors, collectively, the Investors, of a minimum of $2.5 million of Units and up to a maximum of $3 million of Units.
On April 24, 2025, concurrently with the entry into the ATM Sales Agreement (see above), the Company reduced the maximum aggregate offering price registered under the SEPA to zero. 55 Private Placement (January 2024) On January 18, 2024, we entered into a binding term sheet directly with a global investment firm, or the Lead Investor, for the purchase and sale in a private placement, or the January 2024 PIPE, of units, or the Units, consisting of (i) one of our ordinary shares and/or pre-funded warrants to purchase our ordinary shares and (ii) one and a half warrants to purchase our ordinary shares to the Lead Investor and other investors, collectively, the Investors, of a minimum of $2.5 million of Units and up to a maximum of $3 million of Units.
The following table discloses the breakdown of general and administrative expenses: Year ended December 31, Year ended December 31, (in thousands of USD) 2024 2023 Payroll and related expenses 1,733 1,815 Share-based payment 126 212 Professional services 1,593 1,635 Travel expenses 84 61 Rent and office maintenance 138 139 Depreciation 13 20 Marketing and other 488 457 Total 4,175 4,339 Comparison of the Year Ended December 31, 2024, to the Year Ended December 31, 2023 Results of Operations December 31 December 31, (in thousands of USD) 2024 2023 Revenues 1,300 142 Cost of revenues (850 ) (61 ) Gross profit 450 81 Research and development expenses (5,279 ) (7,145 ) General and administrative expenses (4,175 ) (4,339 ) Operating loss (9,004 ) (11,403 ) Financial (expenses) income: Revaluation of derivatives and warrants liabilities (20,181 ) - Other financing income (expenses), net (1,523 ) 255 Net Loss (30,708 ) (11,148 ) Revenues Our revenues for the year ended December 31, 2024, amounted to $1,300,000 representing an increase of $1,158,000 or 815% compared to $142,000 for the year ended December 31, 2023.
The following table discloses the breakdown of general and administrative expenses: Year ended December 31, Year ended December 31, (in thousands of USD) 2025 2024 Payroll and related expenses $ 2,219 $ 1,733 Share-based payment $ 916 $ 126 Professional services $ 1,667 $ 1,593 Travel expenses $ 113 $ 84 Rent and office maintenance $ 158 $ 138 Depreciation $ 6 $ 13 Marketing and other $ 344 $ 488 Total $ 5,423 $ 4,175 Comparison of the Year Ended December 31, 2025, to the Year Ended December 31, 2024 Results of Operations December 31 December 31, (in thousands of USD) 2025 2024 Revenues $ 1,487 $ 1,300 Cost of revenues $ (935 ) $ (850 ) Gross profit $ 552 $ 450 Research and development expenses $ (6,864 ) $ (5,279 ) General and administrative expenses $ (5,423 ) $ (4,175 ) Operating loss $ (11,735 ) $ (9,004 ) Financial (expenses) income: $ $ Revaluation of derivatives and warrants liabilities $ (380 ) $ (20,181 ) Other financing income (expenses), net $ 1,015 $ (1,523 ) Net Loss $ (11,100 ) $ (30,708 ) Revenues Our revenues for the year ended December 31, 2025, amounted to $1,487,000 representing an increase of $187,000, or 14.4% compared to $1,300,000 for the year ended December 31, 2024.
The remaining amount of approximately $3,733 was used for professional services, marketing, travel, rent and other miscellaneous expenses. 52 Net cash used in operating activities of $10,518,000 during the year ended December 31, 2023, was primarily used for payment of an aggregate of approximately $7,486,000 in salaries and related personnel expenses.
The remaining amount of approximately $1,712,000 was used for professional services, marketing, travel, rent and other miscellaneous expenses. Net cash used in operating activities of $9,682,000 during the year ended December 31, 2024, was primarily used for payment of an aggregate of approximately $5,949,000 in salaries and related personnel expenses.
As of the date of this Annual Report, all of the warrants and pre-funded warrants that were issued in connection with the January 2024 PIPE have been exercised in full consisting of 1,394,999 January 2024 PIPE Pre-Funded Warrants, 507,743 Facility Conversion Pre-Funded Warrants, 761,615 Facility Conversion Common Warrants and 4,569,688 January 2024 PIPE Warrants have been exercised resulting in gross proceeds of approximately $5.25 million to the Company.
As of the date of this Annual Report, all of the warrants and pre-funded warrants that were issued in connection with the January 2024 PIPE have been exercised in full consisting of 46,500 January 2024 PIPE Pre-Funded Warrants, 16,925 Facility Conversion Pre-Funded Warrants, 25,387 Facility Conversion Common Warrants and 152,323 January 2024 PIPE Warrants have been exercised resulting in gross proceeds of approximately $5.25 million to the Company.
Research and Development Expenses, net Our research and development expenses consist primarily of salaries and related personnel expenses (including share-based payment), subcontractor’s expenses and other related research and development expenses. 50 The following table discloses the breakdown of research and development expenses: Year ended December 31, Year ended December 31, (in thousands of USD) 2024 2023 Depreciation 134 151 Share-based payment 120 61 Payroll and related expenses 4,216 5,671 Subcontracted work and consulting - 5 R&D consumables 291 696 Rent and office maintenance 413 416 Travel and other expenses 105 145 Total 5,279 7,145 General and Administrative Expenses General and administrative expenses consist primarily of salaries and related expenses, share-based payment, professional service fees for accounting, legal and bookkeeping, facilities, travel expenses and other general and administrative expenses.
The following table discloses the breakdown of research and development expenses: Year ended December 31, Year ended December 31, (in thousands of USD) 2025 2024 Payroll and related expenses $ 5,191 $ 4,216 Share-based payment $ 537 $ 120 Depreciation $ 127 $ 134 $ $ R&D consumables $ 441 $ 291 Rent and office maintenance $ 473 $ 413 Travel and other expenses $ 95 $ 105 Total $ 6,864 $ 5,279 51 General and Administrative Expenses General and administrative expenses consist primarily of salaries and related expenses, share-based payment, professional service fees for accounting, legal and bookkeeping, facilities, travel expenses and other general and administrative expenses.
In the January 2024 PIPE, the Investors purchased $3.0 million of Units consisting of (A) (i) 1,651,458 of ordinary shares and/or (ii) pre-funded warrants to purchase up to 1,394,999 ordinary shares, or the January 2024 PIPE Pre-Funded Warrants and (B) warrants to purchase up to 4,569,688 ordinary shares, or the January 2024 Warrants. The purchase price per Unit is $0.98475.
In the January 2024 PIPE, the Investors purchased $3.0 million of Units consisting of (A) (i) 55,049 of ordinary shares and/or (ii) pre-funded warrants to purchase up to 46,500 ordinary shares, or the January 2024 PIPE Pre-Funded Warrants and (B) warrants to purchase up to 152,323 ordinary shares, or the January 2024 Warrants. The purchase price per Unit is $29.5425.
Discussion regarding our financial condition and results of operations for the year ended December 31, 2023 as compared to the year ended December 31, 2022 is included in Item 5 of our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC on March 28, 2024. 49 Overview We are an early commercialization stage technology company that is seeking to revolutionize railway safety and the data-related market.
Discussion regarding our financial condition and results of operations for the year ended December 31, 2024 as compared to the year ended December 31, 2023 is included in Item 5 of our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on March 31, 2025.
In addition, to date, we have received approximately $12.3 million (gross) as a result of the exercise of warrants issued in the January 2024 PIPE and the Credit Facility in January 2024 and approximately $18.3 million as a result of sales of 22,210,892 of our ordinary shares (not including the Commitment Shares) to Yorkville pursuant to the SEPA.
In addition, to date, we have received approximately $18.3 million as a result of sales of 740,363 of our ordinary shares (not including the Commitment Shares) to Yorkville pursuant to the SEPA.
See “Registered Direct Offering and Concurrent Private Placement of Warrants (May 2023)” and “Private Placement of Ordinary Shares and Warrants (May 2023)”. Standby Equity Purchase Agreement (October 2024) On October 7, 2024, we entered into a Standby Equity Purchase Agreement, or SEPA , with YA II PN, LTD., a Cayman Islands exempt limited partnership, or Yorkville.
Standby Equity Purchase Agreement (October 2024) On October 7, 2024, we entered into a Standby Equity Purchase Agreement, or SEPA, with YA II PN, LTD., a Cayman Islands exempt limited partnership, or Yorkville.
Research and Development Expenses Our research and development expenses for the year ended December 31, 2024, amounted to $5,279,000 representing a decrease of $1,866,00 or 26.1 % as compared to $7,145,000 for the year ended December 31, 2023.
Research and Development Expenses Our research and development expenses for the year ended December 31, 2025, amounted to $6,864,000 representing an increase of $1,585,000, or 30.0% as compared to $5,279,000 for the year ended December 31, 2024.
Since inception, we have not generated significant revenues from the sale of products, and we do not expect to generate significant revenues from the sale of our products in the near future. 55 As of December 31, 2024, our cash and cash equivalents were $17.2 million.
We have incurred losses and generated negative cash flows from operations since inception in April 2016. Since inception, we have not generated significant revenues from the sale of products, and we do not expect to generate significant revenues from the sale of our products in the near future.
The Facility Conversion Pre-Funded Warrant and the Facility Conversion Common Warrant are in substantially the same form and on substantially the same terms as the January 2024 PIPE Pre-Funded Warrant and January 2024 PIPE Ordinary Share Warrant, respectively. See “Item 7.B.—Major Shareholders and Related Party Transactions—Related Party Transactions—Pure Capital—Private Placement (January 2024)” for additional information.
The Facility Conversion Pre-Funded Warrant and the Facility Conversion Common Warrant are in substantially the same form and on substantially the same terms as the January 2024 PIPE Pre-Funded Warrant and January 2024 PIPE Ordinary Share Warrant, respectively.
Financial expense and income: Revaluation of derivatives and warrants liabilities expenses For the year ended December 31, 2024, we recorded expenses in amount of $20,181,000 due to the revaluation of derivatives and warrants liabilities, mainly in connection with warrants issued in a private placement and a convertible loan credit facility that we entered into in January 2024.
This compares to expenses of $20,181,000 for the year ended December 31, 2024, which were primarily related to warrants issued in a private placement and a convertible loan credit facility the Company entered into in January 2024.
The KB Warrants are exercisable at $6.72 per ordinary share. The KB Private Placement closed on June 21, 2023, following approval of such transaction by our shareholders. Current Outlook We have financed our operations to date primarily through proceeds from sales of our equity securities in public and private offerings, as well as a loan from a related party.
As a result of the cashless exercise, we issued 6,033 ordinary shares to such investors. Current Outlook We have financed our operations to date primarily through proceeds from sales of our equity securities in public and private offerings, as well as a loan from a related party.
Each promissory note may be repaid with the proceeds of an Advance or series of Advances under the SEPA or repaid in cash. 53 As of the date of this Annual Report, we have issued an aggregate of 22,210,892 ordinary shares to Yorkville as Advance Shares (not including the Commitment Shares) for aggregate gross proceeds of approximately $18.3 million.
As of the date of this Annual Report, we have issued and sold an aggregate of 740,363 ordinary shares to Yorkville as Advance Shares (not including the Commitment Shares) for aggregate gross proceeds of approximately $18.3 million.
Net Loss As a result of the foregoing, our net loss for the year ended December 31, 2024, was $29,000,000 compared to $11,148,000 for the year ended December 31, 2023, an increase of $18,552,000 or 60%. B.
Net Loss As a result of the foregoing, our net loss for the year ended December 31, 2025, was $11,100,000 compared to $30,708,000 for the year ended December 31, 2024, a decrease of $19,608,000, or 63.8%.
Net cash provided by financing activities in the year ended December 31, 2023, consisted of $5,397,000 in proceeds from the issuance of ordinary shares and warrants, net of issuance expenses, from a series of transactions we executed in May 2023 as detailed below.
Financing Activities Net cash provided by financing activities in the year ended December 31, 2025, consisted of $11,789,000, primarily in proceeds from the issuance of ordinary shares, net of issuance expenses, in relation to the SEPA (as defined below) and the ATM Facility (as defined below) and proceeds from the exercises of January 2024 Facility Warrants.
As of the date of this Annual Report, 17,170,000 January 2024 Facility Warrants have been exercised resulting in gross proceeds of approximately $7.0 million to the Company. See “Item 7.B.—Major Shareholders and Related Party Transactions—Related Party Transactions—Pure Capital—Execution of Credit Facility Agreement and Issuance of Warrant (January 2024)” for additional information.
As of the date of this Annual Report, 572,333 January 2024 Facility Warrants have been exercised resulting in gross proceeds of approximately $7.0 million to us.
This decrease was primarily attributable to a decrease in salaries as part of the process of reducing costs as mentioned above and a decrease in share-based payment expenses of grants which were fully vested or forfeited in 2024. 51 Operating loss As a result of the foregoing, our operating loss for the year ended December 31, 2024, was $9,004,000 compared to an operating loss of $11,403,000 for the year ended December 31, 2023, a decrease of $2,399,000 or 21%.
These increases were partially offset by a decrease in marketing expenses. Operating loss As a result of the foregoing, our operating loss for the year ended December 31, 2025, was $11,735,000 compared to an operating loss of $9,004,000 for the year ended December 31, 2024, an increase of $2,731,000, or 30.3%.
General and administrative expenses Our general and administrative expenses totaled $4,175,000 for the year ended December 31, 2024, representing a decrease of $164,000 or 3.8% compared to $4,339,000 for the year ended December 31, 2023.
Our non-GAAP net loss for the year ended December 31, 2025, was $9,260,000 compared to $10,129,000 for the year ended December 31, 2024, a decrease of $869,000, or 8.6%.
For the year ended December 31, 2023, we did not incur any expenses related to revaluation of derivatives and warrants liabilities. Other financial expenses and income Our other financial expenses amounted to $1,523,00 for the year ended December 31, 2024, a decrease of $1,778,000, or 697%, compared to $255,000 other financial income for the year ended December 31 , 2023.
Other financial expenses and income For the year ended December 31, 2025, our other financial income amounted to $1,015,000, primarily attributable to interest income earned on short-term deposits. This compares to $1,523,00 of other financial expenses for the year ended December 31, 2024.
The decrease was primarily attributable to the full amortization of discount related to a convertible loan credit facility that we entered into in January 2024 and the SEPA set up fees.
The change of $2,538,000 is mainly due to the full amortization of the discount related to the convertible loan credit facility entered into in January 2024, recorded in the year ended December 31, 2024.
Cashless Exercise of Warrants (January 2024) In January 2024, investors from our Private Placement (as defined below) from May 2023 exercised 493,424 Concurrent Warrants on a cashless basis. As a result of the cashless exercise, we issued 181,002 ordinary shares to such investors.
Pursuant to the terms of the January 2024 Facility Warrant, the increase in the beneficial ownership limitation will become effective on the 61 st day after March 5, 2026. Cashless Exercise of Warrants (January 2024) In January 2024, investors from our private placement from May 2023 exercised warrants on a cashless basis.
We have developed cutting edge, AI based, industry-leading detection technology specifically designed for railways. We have developed our railway detection and systems to save lives, increase efficiency, and dramatically reduce expenses for the railway operator.
Overview We are an AI-powered railway technology company in the early commercialization stage, focused on transforming the railway safety and data markets. We believe we have developed cutting edge, industry-leading AI-based detection systems specifically designed for rail applications.